



PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number 10/673,629
		Filing Date September 29, 2003
		First Named Inventor Hector F. DeLuca
		Art Unit 1616
		Examiner Name
Total Number of Pages in This Submission 57		Attorney Docket Number 1256-00923


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Remarks	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Thomas M. Wozny, Reg. No. 28,922 Andrus, Speales, Stark & Sawall, LLP
Signature	
Date	January 19, 2004

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Dorothy A. Hauser	
Signature		Date January 19, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



THIS PAGE BLANK (USPTO)



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/673,629

Applicant : Hector F. DeLuca et al

Filed : September 29, 2003

Title : Use of 2-Methylene-19-Nor-
20(S)-1 α ,25-
Dihydroxyvitamin D₃ to
Increase Bone Strength

TC/A.U. : 1616

Examiner :

Docket No. : 1256-00923

) CERTIFICATE OF MAILING

) I hereby certify that this correspondence
is being deposited with the United States
Postal Service with sufficient postage as
first class mail in an envelope addressed
to: Commissioner of Patents, P.O. Box
1450, Alexandria, VA 22313-1450, on
this 19th day of January, 2004.

)

) 
January 19, 2004
Dorothy A. Hauser Date

INFORMATION DISCLOSURE STATEMENT

Mail Stop: IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references listed on the enclosed PTO Form 1449 are being submitted in
the above-identified patent application in accordance with 37 CFR 1.97(b)(3).

A copy of each of the listed references is enclosed in compliance with the rules.

Respectfully submitted,

ANDRUS, SCEALES, STARKE & SAWALL, LLP


By



Thomas M. Wozny

Reg. No. 28,922

Andrus, Sceales, Starke & Sawall, LLP
100 East Wisconsin Avenue, Suite 1100
Milwaukee, WI 53202
(414) 271-7590



THIS PAGE BLANK (USPTO)



PTO/SB/08A (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>		Complete if Known	
		Application Number	10/673,629
		Filing Date	September 29, 2003
		First Named Inventor	Hector F. DeLuca
		Art Unit	1616
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	1256-00923

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

U. S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



THIS PAGE BLANK (USPTO)



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				C <i>mpl</i> te if Known	
				Application Number	10/673,629
				Filing Date	September 29, 2003
				First Named Inventor	Hector F. DeLuca
				Art Unit	1616
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	1256-00923

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		The Merck Manual, Sixteenth Edition, 1992, pg. 1357.		
		Boris et al, "Relative Activities of Some Metabolites and Analogs of Cholecalciferol in Stimulation of Tibia Ash Weight in Chicks Otherwise Deprived of Vitamin D," Vitamin D Metabolites, Analogs and Bone Ash, 1976, pp. 194-198.		
		Hedlund et al, "Increased Incidence of Hip Fracture in Osteoporotic Women Treated with Sodium Fluoride," Journal of Bone and Mineral Research, Vol. 4, No. 2, 1989, pp. 223-225.		
		Holick et al, Harrison's Principle of Internal Medicine, 13th Ed. 1994, pp. 2137-2151.		
		Jensen et al, "Treatment of Post Menopausal Osteoporosis, A Controlled Therapeutic Trial Comparing Oestrogen/Gestagen, 1,25-Dihydroxy-Vitamin D-3 and Calcium," Clinical Endocrinology, 16, 1982, pp. 515-524		
		Meunier, "Evidence-Based Medicine and Osteoporosis: A Comparison of Fracture Risk Reduction Data from Osteoporosis Randomised Clinical Trials," IJCP, Vol. 53, No. 2, March, 1999.		
		Nordin et al, "The Metabolic Basis of Osteoporosis," Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp.23-36.		
		Ott et al, "Calcitriol Treatment is not Effective in Postmenopausal Osteoporosis," Annals of Internal Medicine, Vol. 110, No. 4, February 15, 1989, pp. 267-274.		
		Peck, "The Pathogenesis of Postmenopausal Osteoporosis," Osteoporosis: Physiological Basis, Assessment, and Treatment, Elsevier Science Publishing Co., Inc., 1990, pp. 3-6.		
		Riggs et al, "Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures without Commensurate Increases in Bone Density," Journal of Bone and Mineral Research, Vol. 17, No. 1, 2002, pp. 11-13.		

Examiner Signature	Date Considered	
-------------------------------	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



THIS PAGE BLANK (USPTO)



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				C mplete if Known	
				Application Number	10/673,629
				Filing Date	September 29, 2003
				First Named Inventor	Hector F. DeLuca
				Art Unit	1616
Examiner Name					
Sheet	3	of	3	Attorney Docket Number	1256-00923


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Riggs et al, "Causes of Age-Related Bone Loss and Fractures," <i>Osteoporosis: Physiological Basis, Assessment, and Treatment</i> , 1990, pp. 7-16.	
		Christensen, Abstract PMID: 6795047, "Effect of 1,25-Dihydroxy-Vitamin D3 in Itself or Combined with Hormone Treatment in Prevent Postmenopausal Osteoporosis," <i>Eur. J. Clin. Invest.</i> , August 11, 1981, Vol. 11, No. 4.	
		Klein, "Nutritional Rickets and Osteomalacia," <i>Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism</i> , 1996, pp. 301-305.	
		Kleereker, "Treatment of Osteoporosis with Sodium Fluoride Alternating with Calcium and Vitamin D," <i>Osteoporosis: Recent Advances in Pathogenesis and Treatment</i> , 1981, pp. 441-448.	
		Sarkar, "Relationships Between Bone Mineral Desity and Incident Vertebral Fracture Risk with Raloxifene Therapy," <i>Journal of Bone and Mineral Research</i> , Vol. 17, No. 1, 2002, pp. 1-10.	
		Cummings et al, "Improvement in Spine Bone Desity and Reduction in Risk of Vertebral Fractures During Treatment with Antiresorptive Drugs," <i>The American Journal of Medicine</i> , Vol. 112, 2002, pp. 281-289.	
		Sudhaker Rao et al, "Metabolic Bone Disease in Gastrointestinal Hepatobiliary, and Pancreatic Disorders," <i>Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism</i> , 1996, pp. 306-311.	
		Watts et al, "Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis," <i>The New England Journal of Medicine</i> , Vol. 323, No. 2, July 12, 1990, pp. 73-79.	
		Harris, "Four-Year Study of Intermittent Cyclic Etidronate Treatment of Postmenopausal Osteoporosis: Three Years of Blinded Therapy Followed by One Year of Open Therapy," <i>The American Journal of Medicine</i> , Vol. 95, December 1993, pp. 557-567.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



THIS PAGE BLANK (USPTO)